Hims & Hers Aims to Double-Down on Growth Over Sale as Canada and Novo Nordisk Catalysts Loom

The past week has been a whirlwind for Hims & Hers, with insider selling and institutional shifts fueling intense debate. On one side, executives and employees have been selling shares, a classic sign of personal liquidity events or perhaps a lack of conviction in the stock's premium price. On the other, major funds like JPMorgan have been quietly buying, adding to their stakes. This split in behavior highlights a clear divide among investors about the company's long-term outlook. Yet, for all the noise, the real story is written in the numbers and the company's own bold plan.

The financials from 2025 tell a powerful tale of independent growth. Revenue surged to $2.35 billion, a remarkable 59% increase year-over-year. More importantly, that growth came from a deepening relationship with its customer base, which expanded to over 2.5 million subscribers. That's not just a number; it's a sign of a platform people keep coming back to. The company is building a durable business, not just chasing a quick sale.

That's why the acquisition rumors ring hollow. The company is laser-focused on scaling its own empire. Its next major move is a strategic expansion into Canada, set to launch this year. This isn't a random geographic hop. It's a calculated play timed perfectly with the anticipated first-ever availability of generic semaglutide in the world. With almost two-thirds of Canadian adults overweight or obese, and branded weight loss drugs costing over C$200 a month, Hims & Hers sees a massive, underserved market. By offering a digital platform with licensed providers and lower-cost generics, it's aiming to become the go-to for affordable, high-quality care. This plan to enter a new country and launch a flagship product simultaneously is the definition of choosing growth over a sale.

The bottom line is that Hims & Hers is betting on its own ability to execute. The insider selling and institutional debate are just background noise. The company's proven 2025 performance and its ambitious, well-timed expansion into Canada show a management team confident in its product, its brand, and its path forward. In a world of complex financial engineering, that's a simple, powerful story.

The Growth Engine: Acquisitions, Partnerships, and Platform Power

The real story of Hims & Hers' independence isn't in the rumors of a sale. It's in the deliberate, multi-pronged strategy it's building to grow its own empire. This isn't about waiting for a buyer; it's about actively constructing a global platform, one acquisition and partnership at a time.

The company's growth engine is firing on all cylinders. Its core platform is proving its real-world utility, with the subscriber base expanding by 13% year-over-year to over 2.5 million. This isn't just a number; it's a sign of a service people find indispensable. The model works because it integrates everything a customer needs-telehealth consultations, diagnostic testing, and treatment-into a single, convenient experience. This integrated approach, which includes new offerings like menopause care and multi-cancer screening, creates a sticky ecosystem that keeps users coming back.

A key part of that expansion is a bold acquisition strategy. Hims & Hers just announced it will acquire Eucalyptus, a digital health leader in Australia, the UK, and Germany. This deal is a direct play to scale internationally and accelerate its vision to become a global consumer health platform. The company has a clear target: hitting over $1 billion in international revenue within three years. By bringing Eucalyptus's local expertise and operations into its fold, Hims & Hers can replicate its successful US model faster and more effectively in key European and Asian markets.

Then there's the Novo Nordisk partnership, which was initially framed as a potential retreat but is actually a powerful growth catalyst. The deal resolves a costly legal overhang and gives Hims & Hers a new, high-demand product to sell. It allows the company to offer Novo Nordisk's Wegovy and Ozempic drugs through its platform, starting later this month. This is a win-win: Novo gets access to Hims & Hers's massive customer base, and Hims & Hers gains a premium, in-demand product to drive new revenue and attract more users. It removes a legal threat and turns it into a commercial opportunity.

The bottom line is that Hims & Hers is executing a classic, smart growth playbook. It's using acquisitions to rapidly scale its geographic reach, partnerships to add high-margin products, and its integrated platform to deepen customer relationships. This isn't complex financial engineering. It's about building a durable business that people rely on. For a company with a proven 59% revenue growth rate and a clear path to international dominance, that's a much more compelling story than any potential sale.

The Financial Kick the Tires: Quality, Margin, and the Path Forward

Let's kick the tires on the financials. The numbers from 2025 show a company building real quality. It posted $128 million in net income on a massive revenue surge, and its gross margin sits around 60.86%. That's a powerful combination. It means the core business is not just growing fast, but it's also profitable and efficient. This isn't a startup burning cash; it's a platform generating real cash flow from its existing customer base.

The new Novo Nordisk deal changes the margin math, and that's a key point to watch. The company will now sell branded Wegovy and Ozempic pills at prices set by Novo Nordisk. This turns Hims & Hers from a profit-maximizing middleman back into a standard distributor. As one analysis notes, this will "crush" margins compared to the days when it sold its own compounded versions. The profit per customer is expected to shrink significantly. That's a clear headwind. The stock's recent pop priced in a clean legal overhang and a revenue boost, but the margin compression is the new reality.

So, is the growth story sustainable? The answer hinges on one critical metric: volume. The deal drives revenue growth, but only if Hims & Hers can leverage its platform to sell a lot of these branded drugs. The company has a huge customer base, but now it faces intense competition. Amazon just entered the market, and every other telehealth player is fighting for the same customers. Without its cheaper compounded alternative as a unique hook, Hims & Hers must spend more on marketing-already a hefty 40% of revenue-just to stay in the game.

The bottom line is that the company is trading a high-margin, legally risky past for a lower-margin, but stable, future. The smart money will watch to see if it can use its brand and platform to drive consistent volume under this new deal. If it can, the growth will be real and durable. If it can't, the stock may struggle to justify its valuation after the initial rally. For now, the financials pass the smell test for quality, but the path forward requires proving it can sell volume at a lower profit.

Catalysts and Risks: What to Watch for the Thesis

The independent growth thesis now hinges on a few clear, near-term events. The major catalyst is the successful launch of the Novo Nordisk drugs on its platform, paired with the planned entry into Canada. The company just announced it will offer Novo Nordisk's Wegovy and Ozempic drugs later this month. This is a direct revenue driver, resolving a costly legal overhang and giving Hims & Hers a premium product to sell. Simultaneously, it is moving into Canada, a market of almost two-thirds of adults overweight or living with obesity, timed with the anticipated first-ever availability of generic semaglutide. If both launches execute smoothly, they could provide a powerful double-digit revenue boost and validate the company's expansion playbook.

Yet, a key risk is already in the open: margin pressure. The new partnership turns Hims & Hers into a distributor, selling branded drugs at Novo Nordisk's prices. This will "crush" margins compared to its previous model of selling compounded versions. The company's profit per customer is expected to shrink significantly. That's the new reality. The stock's recent pop priced in a clean legal overhang, but the margin compression is the headwind that will test the thesis. The company must now prove it can sell enough volume to offset lower per-unit profits.

Then there's the competitive intensity. Hims & Hers no longer has a unique, low-cost product to hide behind. Amazon just entered the market, and every other telehealth player is fighting for the same customers. The company already spends a hefty 40% of revenue on marketing. Without its cheaper compounded alternative as a unique hook, it may need to spend even more just to stay in the game, further pressuring margins.

Finally, the need to watch execution on its ambitious international expansion is critical. The company just agreed to acquire Eucalyptus, a digital health leader in Australia, the UK, and Germany. This deal is meant to accelerate its vision to become a global platform. The company aims for over $1 billion in international revenue within three years. But scaling that model requires flawless integration and local execution. The bottom line is that the thesis is now about volume, not just growth. The company must sell a lot of branded drugs at lower margins while also successfully launching in Canada and integrating Eucalyptus. If it can do that, the growth story remains intact. If it struggles, the stock may have to reprice.